AtriCure (NASDAQ:ATRC) Director Sells $107,160.00 in Stock

AtriCure, Inc. (NASDAQ:ATRC) Director Maggie Yuen sold 3,000 shares of the business’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $35.72, for a total value of $107,160.00. Following the transaction, the director directly owned 11,371 shares of the company’s stock, valued at approximately $406,172.12. This represents a 20.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

AtriCure Stock Down 6.4%

Shares of NASDAQ:ATRC opened at $36.03 on Friday. AtriCure, Inc. has a fifty-two week low of $28.29 and a fifty-two week high of $43.11. The firm’s 50 day moving average price is $35.12 and its 200 day moving average price is $34.24. The company has a quick ratio of 2.83, a current ratio of 3.94 and a debt-to-equity ratio of 0.16. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -59.06 and a beta of 1.56.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.10. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.56%. The company had revenue of $134.27 million during the quarter, compared to analysts’ expectations of $131.25 million. During the same quarter in the previous year, the business posted ($0.17) EPS. The firm’s revenue was up 15.8% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. As a group, equities research analysts predict that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ATRC has been the topic of several recent analyst reports. Canaccord Genuity Group increased their target price on AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wall Street Zen raised AtriCure from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.22.

Institutional Trading of AtriCure

A number of large investors have recently made changes to their positions in ATRC. Oberweis Asset Management Inc. purchased a new position in AtriCure during the 3rd quarter worth approximately $5,411,000. Voloridge Investment Management LLC lifted its stake in AtriCure by 1.5% in the third quarter. Voloridge Investment Management LLC now owns 273,749 shares of the medical device company’s stock valued at $9,650,000 after buying an additional 4,041 shares during the last quarter. Verition Fund Management LLC boosted its holdings in shares of AtriCure by 126.8% in the third quarter. Verition Fund Management LLC now owns 17,752 shares of the medical device company’s stock valued at $626,000 after acquiring an additional 9,924 shares during the period. Qube Research & Technologies Ltd grew its position in shares of AtriCure by 203.6% during the third quarter. Qube Research & Technologies Ltd now owns 94,729 shares of the medical device company’s stock worth $3,339,000 after acquiring an additional 63,531 shares during the last quarter. Finally, Focus Partners Wealth increased its holdings in shares of AtriCure by 10.1% in the 3rd quarter. Focus Partners Wealth now owns 19,880 shares of the medical device company’s stock valued at $691,000 after acquiring an additional 1,824 shares during the period. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.